MedChemExpress MCE - Products
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use.
| Product | Description | |
|---|---|---|
| CCR4 antagonist 4 | CCR4 antagonist 4 (compound 22) is a selective and potent antagonist of the CC chemokine receptor-4 (CCR4), with an IC50 of 0.02 μM. CCR4 antagonist 4 also blocks MDC-mediated chemotaxis (IC50: 0.007 μM) and Ca2+ mobilization (IC50: 0.003 μM). CCR4 antagonist 4 can be used for allergic inflammation research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 668980-17-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-157453. |  |
| CCR6 antagonist 1 | CCR6 antagonist 1 is a CCR6 antagonist that inhibits the CCL20/CCR6 axis. CCR6 antagonist 1 can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 588674-64-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-151435. | |
| CCR6 inhibitor 1 | CCR6 inhibitor 1 is a potent and selective CCR6 inhibitor, with IC50s of 0.45 and 6 nM for monkey and human CCR6, much more selective at CCR6 over human CCR1 (IC50, > 30000 nM), and CCR7 (IC50, 9400 nM). CCR6 inhibitor 1 markedly blocks ERK phosphorylation. CCR6 inhibitor 1 is used in the research of autoimmune diseases and cancer[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2437547-04-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-112701. | |
| CCR7 Ligand 1 | CCR7 Ligand 1 (CCR7-Cmp2105) is an allosteric Ligand and antagonist for human CC chemokine receptor 7 (CCR7) with a Kd of 3 nM. CCR7 Ligand 1, thiadiazole-dioxide ligan, suppresses arrestin binding in response to activation by CCL19 with an IC50 of 7.3 μM[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: CCR7-Cmp2105. CAS No. 681514-83-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg. Product ID: HY-133073. | |
| CCT018159 | CCT018159 is an ATP-competitive HSP90β inhibitor, with an IC50 of 3.2 μM against human HSP90β ATPase and 6.6 μM against yeast HSP90β ATPase. CCT018159 induces cell cycle arrest and apoptosis in tumor cells, and inhibits invasion and angiogenesis. CCT018159 is applicable to cancer-related research[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 171009-07-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg. Product ID: HY-110042. | |
| CCT020312 | CCT020312 is a selective EIF2AK3/PERK activator. CCT020312 elicits EIF2A phosphorylation in cells. Uses: Scientific research. Category: Signaling pathways. CAS No. 324759-76-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-119240. | |
| CCT036477 | CCT036477 is a Wnt/β-catenin pathway inhibitor. CCT036477 blocks transcription at β-catenin without altering its levels. CCT036477 inhibits proliferation of various cancer cells, development of embryos, and expression of Wnt target genes (PPARδ, Cyclin D1, TCF4, and ID2)[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 305372-78-5. Pack Sizes: 5 mg; 10 mg; 25 mg. Product ID: HY-119966. | |
| CCT128930 | CCT128930 is a ATP-competitive and selective inhibitor of AKT (IC50=6 nM for AKT2). CCT128930 has 28-fold selectivity over the closely related PKA kinase (IC50=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC50=120 nM). Antitumor activity. Uses: Scientific research. Category: Signaling pathways. CAS No. 885499-61-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13260. | |
| CCT129957 | CCT129957 is an indole derivative and a potent phospholipase C-γ (PLC-γ) inhibitor with an IC50 of ~3 μM and a GC50 of 15 μM. CCT129957 inhibits Ca2+ release in squamous carcinoma cells at ~15 μM[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 883098-58-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111208. | |
| CCT 137690 | CCT 137690 is a potent and orally available aurora kinase inhibitor with IC50s of 15, 25, and 19 nM for aurora A, B and C, respectively. Uses: Scientific research. Category: Signaling pathways. CAS No. 1095382-05-0. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10804. | |
| CCT241533 hydrochloride | CCT241533 hydrochloride is a potent and selective CHK2 inhibitor with an IC50 of 3 nM and a Ki of 1.16 nM[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1431697-96-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-14715B. | |
| CCT245737 | CCT245737 (SRA737) is an orally active and seletive Chk1 inhibitor, with an IC50 of 1.3 nM. Uses: Scientific research. Category: Signaling pathways. Alternative Names: SRA737. CAS No. 1489389-18-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18958. | |
| CCT251545 | CCT251545 is an orally bioavailable and potent inhibitor of WNT signaling with an IC50 of 5 nM in 7dF3 cells[1]. CCT251545 is a selective chemical probe for exploring the role of CDK8 and CDK19 in human disease[2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1661839-45-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12681. | |
| CCT-251921 | CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC50 of 2.3 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1607837-31-9. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19984. | |
| CCT365623 hydrochloride | CCT365623 hydrochloride is an orally active lysyl oxidase (LOX) inhibitor, with an IC50 of 0.89 μM. CCT365623 hydrochloride suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 hydrochloride is extremely well tolerated, and has good pharmacokinetic properties[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2126136-98-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-124674A. | |
| CCT373566 | CCT373566 is a potent and orally active molecular glue degrader of transcriptional repressor BCL6, with an IC50 of 2.2 nM. CCT373566 shows strong antiproliferative efficacy in vitro and reduction in tumor growth in vivo[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2378853-66-6. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-146185. | |
| CCW16 | CCW16 is a cofactor for the synthesis of protein degraders, such as PROTACs CCW 28-3 (HY-156774). Uses: Scientific research. Category: Signaling pathways. CAS No. 2361138-33-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-143346. | |
| CCW 28-3 | CCW 28-3 is a PROTAC-based BRD4 degrader in a proteasome- and RNF4-dependent manner (Pink: JQ-1 (carboxylic acid) (HY-78695); Black: linker (HY-170384); Blue: RNF4 ligand CCW16 (HY-143346))[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2361142-23-4. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-156774. | |
| CD00509 | CD00509 is a tyrosyl-DNA phosphodiesterase (PDE) Tdp1 inhibitor with an IC50 of 0.71 μM. CD00509 increases DNA damage and promotes apoptosis of MCF-7 cells. CD00509 can sensitize breast cancer cells and wild-type murine embryonic fibroblasts (MEFs) to Camptothecin (CPT) (HY-16560). CD00509 can be used for the study of cancers such as breast cancer[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 27430-18-8. Pack Sizes: 5 mg; 10 mg. Product ID: HY-W177546. | |
| CD1530 | CD1530 is an orally active, selective RARγ agonist and antibacterial agent. CD1530 reduces Smad1/5/8 phosphorylation and overall Smad levels. CD1530 reduces β-catenin, MMP9 protein, and ROS levels. CD1530 exhibits activities such as inhibiting heterotopic ossification, promoting Achilles tendon healing, and inhibiting muscle fatty infiltration. CD1530 can be used in the research of orthopedic diseases (such as heterotopic ossification, Achilles tendon injury), muscle diseases (such as muscle fatty infiltration-related diseases)[1][2][3][4][5][6]. Uses: Scientific research. Category: Signaling pathways. CAS No. 107430-66-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108527. | |
| CD2665 | CD2665 is an orally active and selective RAR-β,γ antagonist, with Kd values of 306 nM, 110 nM for RAR-β and RAR-γ, repectively[1][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 170355-78-9. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-107437. | |
| CD33 splicing modulator 1 | CD33 splicing modulator 1 (Compound 1) is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. CD33 splicing modulator 1 increases exon 2 skipping in cellular mRNA pools. CD33 splicing modulator 1 has the potential for the research of neurodegenerative disease including Alzheimer's disease[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2762547-05-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-144399. | |
| CD38 inhibitor 1 | CD38 inhibitor 1 (compound 78c) is a potent CD38 inhibitor with IC50s of 7.3 nM and 1.9 nM for hCD38 and mouse CD38[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1700637-55-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg; 500 mg. Product ID: HY-123999. | |
| CD39-IN-1 | CD39-IN-1 is a selective CD39 inhibitor with an IC50 value of 68.7 nM. CD39-IN-1 exerts antiproliferative effects on tumor cells and shows low toxicity to normal cell lines. CD39-IN-1 inhibits CD39-mediated eATP hydrolysis in the ATP-adenosine pathway. CD39-IN-1 is applicable for tumor-related research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3097380-98-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-174341. | |
| CD437 | CD437 is a selective Retinoic Acid Receptor γ (RARγ) agonist. Uses: Scientific research. Category: Signaling pathways. Alternative Names: AHPN. CAS No. 125316-60-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100532. | |
| CD532 | CD532 is a potent Aurora A kinase inhibitor with an IC50 of 45 nM. CD532 has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 also can directly interact with AURKA and induces a global conformational shift. CD532 can be used for the research of cancer[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1639009-81-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg. Product ID: HY-112273. | |
| CDAP | CDAP is an organic cyanylating reagent that can be used for preparation of solid phase affinity reagents, modification of protein thiols and nucleotide delivery. CDAP also activates polysaccharides with a variety of chemical properties. CDAP can be used to prepare conjugate vaccines and other immune reagents[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 59016-56-7. Pack Sizes: 10 mM * 1 mL in DMSO; 100 mg; 250 mg; 500 mg; 1 g; 5 g. Product ID: HY-W012184. | |
| Cdc7-IN-1 | Cdc7-IN-1 (Compound 13) is a highly potent, selective and ATP competitive inhibitor of Cdc7 kinase, with an IC50 value of 0.6 nM at 1 mM ATP and with slow off-rate characteristics. Cdc7-IN-1 potently inhibits Cdc7 activity in cancer cells, and effectively induces cell death[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1402055-25-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-101523. | |
| CDD-1653 | CDD-1653 is a potent and selective BMPR2 inhibitor (IC50=2.8 nM). CDD-1653 reduces the ability of ATP to bind to the kinase domain of BMPR2, thereby affecting the phosphorylation of SMAD1/5/8 transcription factors, which play a key role in the BMP signaling pathway. CDD-1653 can be used to study diseases related to the BMP signaling pathway[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3034216-44-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-164145. | |
| CDD-2789 | CDD-2789 is a potent and selective ALK2 inhibitor with an IC50 0.54 μM and a Kd of 2.1 nM, respectively. CDD-2789 exhibits >120-fold selectivity over ALK3/5/6. CDD-2789 reduces activin A- and BMP2-induced SMAD1/5 phosphorylation in fibroblasts. CDD-2789 can be used for ALK2-related cancer research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3052084-77-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-173149. | |
| CDD-2807 | CDD-2807 is an inhibitor for serine/threonine kinase 33 (STK33) with IC50 of 9.2 nM. CDD-2807 exhibits no significant toxicity in mice and can cross the blood-testis barrier without accumulating in the brain. CDD-2807 induces a reversible contraceptive effect and has potential for the development of the male contraceptive[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3086536-23-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-162565. | |
| CDDO-biotin | CDDO-biotin is an IKKβ inhibitor with cancer cell inhibitory activity. CDDO-biotin directly interacts with and oxidizes Cys-179 in the activation loop of IKKβ, forming an adduct with wild-type IKKβ. CDDO-biotin can be used in the research of myeloid leukemia, osteosarcoma, multiple myeloma, lung cancer, breast cancer and pancreatic cancer[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3110422-01-7. Pack Sizes: 5 mg; 10 mg; 25 mg. Product ID: HY-186167. | |
| CDDO-dhTFEA | CDDO-dhTFEA (RTA dh404) is a synthetic oleanane triterpenoid compound which potently activates Nrf2 and inhibits the pro-inflammatory transcription factor NF-κB[1]. CDDO-dhTFEA restores hypertension (MAP), increases Nrf2 and expression of its target genes, attenuates activation of NF-κB and transforming growth factor-β pathways, and reduces glomerulosclerosis, interstitial fibrosis and inflammation in the chronic kidney disease (CKD) rats[2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: RTA dh404. CAS No. 1191265-33-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112671. | |
| CDDO-EA | CDDO-EA is an NF-E2 related factor 2/antioxidant response element (Nrf2/ARE) activator. Uses: Scientific research. Category: Signaling pathways. Alternative Names: CDDO ethyl amide; TP319; RTA 405. CAS No. 932730-51-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12213. | |
| CDDO-Im | CDDO-Im (RTA-403) is an activator of Nrf2 and PPAR, with Kis of 232 and 344 nM for PPARα and PPARγ[1][2]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: RTA-403; TP-235; CDDO-Imidazolide. CAS No. 443104-02-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15725. | |
| CDH11-IN-1 | CDH11-IN-1 is a CDH11 inhibitor. CDH11-IN-1 regulates CDH11-mediated biological pathways. CDH11-IN-1 can be used for research on cancer and rheumatoid arthritis[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1239467-61-8. Pack Sizes: 10 mM * 1 mL in DMSO; 25 mg; 50 mg; 100 mg. Product ID: HY-177575. | |
| c-di-AMP disodium | c-di-AMP (Cyclic diadenylate) sodium is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP sodium is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP sodium acts as a potent mucosal adjuvant stimulating both humoral and cellular responses[1][2][3][4]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Cyclic diadenylate disodium; Cyclic-di-AMP disodium. CAS No. 2734909-87-4. Pack Sizes: 10 mM * 1 mL in DMSO; 500 μg; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12326A. | |
| C-DIM12 | C-DIM12 is a potent, orally active Nurr1 modulator. C-DIM12 inhibits the tumor growth and autophagy, and induces the cell apoptosis. C-DIM12 has anti-inflammatory and neuroprotective effects, and can be used for cancer and neurological disease study[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: DIM-C-pPhCl. CAS No. 178946-89-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19808. | |
| CDK12/13-IN-3 | CDK12/13-IN-3 (Compound 12b) is the orally active inhibitor for CDK that inhibits CDK12 and CDK13 with IC50 of 107.4 nM and 79.4 nM. CDK12/13-IN-3 inhibits the phosphorylation of Ser2 on the CTD of RNA polymerase II, induces DNA damage, and downregulates the gene expression of DNA damage response (DDR). CDK12/13-IN-3 exhibits antiproliferative activity against multiple cancer cells with IC50 of nanomolar levels. CDK12/13-IN-3 exhibits antitumor effect in mouse models, exhibits good pharmacokinetic properties with an oral bioavailability of 53.6%[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3029608-57-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-173059. | |
| CDK12-IN-2 | CDK12-IN-2 is a potent, selective and nanomolar CDK12 inhibitor (IC50=52 nM) with good physicochemical properties. CDK12-IN-2 is also a strong CDK13 inhibitor due to CDK13 is the closest homologue of CDK12. CDK12-IN-2 shows excellent kinase selectivity for CDK12 over CDK2, 9, 8, and 7. CDK12-IN-2 inhibits the phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II. CDK12-IN-2 can be used an excellent chemical probe for functional studies of CDK12[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2244987-03-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112626. | |
| CDK12-IN-3 | CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC50 of 491 nM in enzymatic assay. Uses: Scientific research. Category: Signaling pathways. CAS No. 2220184-50-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112261. | |
| CDK12-IN-8 | CDK12-IN-8 (Compound Cpd143) is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). CDK12-IN-8 inhibits CDK12-mediated phosphorylation of the C-terminal domain (CTD) serine 2 of RNA polymerase II, interfering with gene transcription elongation and DNA damage repair pathways. CDK12-IN-8 is promising for research of cancers with high CDK12 expression such as small cell lung cancer and triple-negative breast cancer[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2928619-86-5. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-171786. | |
| Cdk1/2 Inhibitor III | Cdk1/2 Inhibitor III (compound 3n) is a highly potent and selective Cdk1/cyclin B and Cdk2/cyclin A inhibitor of with IC50s of 0.6 nM and 0.5 nM, respectively. Cdk1/2 Inhibitor III shows selectivity over VEGF-R2 (IC50 of 32 nM), GSK-3β (IC50 of 140 nM), and a other kinases. Cdk1/2 Inhibitor III inhibits in cell proliferation with IC50s of 20 nM, 35 nM and 92 nM for HCT-116, HeLa, and A375 cells, respectively[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 443798-55-8. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-112462. | |
| CDK2 degrader 1 | CDK2 degrader 1 (Compound 3) is a selective CDK2 molecular glue degrader with a Dmax (CDK2) of > 80% and a Ki (CRBN) > 1 μM. CDK2 degrader 1 binds to cereblon to induce ubiquitination and subsequent proteasomal degradation of the CDK2. CDK2 degrader 1 is used in the research of a wide range of cancers[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3036604-59-5. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-163814. | |
| CDK2 degrader 2 | CDK2 degrader 2 (Compound I-10) is a PROTAC degrader for CDK2 that degrades CDK2 in MKN1 cell with a DC50 <100 nM[1]. (Pink: ligand for target protein (HY-176124); Black: linker (HY-W687952); Blue: ligand for E3 ligase CRBN (HY-45512)). Uses: Scientific research. Category: Signaling pathways. CAS No. 3030271-16-7. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-163815. | |
| CDK2 degrader 3 | CDK2 degrader 3 is a selective CDK2 molecular glue-like degrader. CDK2 degrader 3 induces G1 cell cycle arrest in CCNE1-amplified cancer cells. CDK2 degrader 3 is applicable to breast cancer-related research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2862772-71-0. Pack Sizes: 1 mg; 5 mg. Product ID: HY-164827. | |
| CDK2 degrader 4 | CDK2 degrader 4 (compound 104) is a potent CDK2 degrader. CDK2 degrader 4 has the potential for the research of cancer[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2924122-01-8. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-169910. | |
| CDK2 degrader 5 | CDK2 degrader 5 is a CRBN-binding CDK2 molecular glue degrader. CDK2 degrader 5 induces ubiquitination and subsequent proteasomal degradation of CDK2. CDK2 degrader 5 can be used for the research of cancer[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2923574-11-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-169912. | |
| CDK2 degrader 6 | CDK2 degrader 6 is an orally active and potent CDK2 molecular glue degrader with a DC50 of 46.5 nM. CDK2 degrader 6 binds to cereblon and CDK2 to induce ubiquitination and subsequent proteasomal degradation of CDK2. CDK2 degrader 6 modulates cell cycle in breast cancer cells. CDK2 degrader 6 reduces proliferation of breast cancer cells. CDK2 degrader 6 exhibits in vivo antitumor activity in gastric cancer mouse models. CDK2 degrader 6 can be used for the research of breast cancer, gastric cancer[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3036606-92-2. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-176444. | |
| CDK2 degrader 7 | CDK2 degrader 7 is an orally active CDK2 degrader, with DC50 values of 13 nM (MKN1cells) and 17 nM (TOV21G cells). CDK2 degrader 7 induces G1 phase arrest in MKN1 cells. CDK2 degrader 7 achieves tumor stasis in HCC1569 (CCNE1-amplified) xenograft models. CDK2 degrader 7 can be used for the study of CCNE1-amplified cancers[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3030279-55-8. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-175842. | |
| CDK2-IN-30 | CDK2-IN-30 is a CDK2 inhibitor with an IC50 value ≤20 nM. CDK2-IN-30 modulates CDK2 activity to influence cell cycle regulation. CDK2-IN-30 can be used for the research of cancer[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2640038-22-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-164664. | |
| CDK2-IN-31 | CDK2-IN-31 is a CCNE1:CDK2 complex inhibitor with an IC50 of 0.13 μM. CDK2-IN-31 binds to a cryptic allosteric pocket at the CCNE1:CDK2 interface, inducing structural rearrangements of the CDK2 A-loop that disrupt the kinase's active conformation and interfere with substrate binding. CDK2-IN-31 inhibits phosphorylation of retinoblastoma protein 1 (RB1) in CCNE1-dependent ovarian cancer cells. CDK2-IN-31 impairs coenrichment of protein PRC1 with CCNE1-N112C:CDK2 complexes. CDK2-IN-31 can be used for the research of ovarian cancer[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2813260-27-2. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-159805. | |
| CDK2-IN-4 | CDK2-IN-4 (compound 73) is a potent and selective CDK2 inhibitor with an IC50 of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2079895-42-2. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-117535. | |
| CDK2/MDM2-IN-1 | CDK2/MDM2-IN-1 (III-13) is a dual inhibitor of CDK2/MDM2 with an IC50 value of 2.60 nM for CDK2. CDK2/MDM2-IN-1 has antitumor activity[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3083904-06-4. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-163357. | |
| CDK4/6-IN-18 | CDK4/6-IN-18 (Example 2BrIC) is a selective CDK4/6 inhibitor. CDK4/6-IN-18 inhibits ionizing radiation (IR)-induced DNA damage in cells[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 546102-60-7. Pack Sizes: 500 μg; 1 mg. Product ID: HY-112418. | |
| CDK4/6-IN-2 | CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor extracted from patent US20180000819A1, Compound 1, has IC50s of 2.7 and 16 nM for CDK4 and CDK6, respectively[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1800506-48-2. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-114339. | |
| CDK4 degrader 1 | CDK4 degrader 1 (ML 1-71) is a molecular glue degrader that targets CDK4[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3094209-58-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-163640. | |
| CDK5-IN-1 | CDK5-IN-1 is a potent CDK5 inhibitor with an IC50 less than 10 nM. CDK5-IN-1 is greater than 100-fold more active against CDK5 than CDK2. CDK5-IN-1 is used for kidney diseases research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2639540-19-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139725. | |
| CDK5 inhibitor 20-223 | CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC50s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: CP668863. CAS No. 865317-30-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-123772. | |
| CDK6-IN-1 | CDK6-IN-1 (compound 4i) is a CDK6 inhibitor. CDK6-IN-1 inhibits cell growth and induces cell cycle arrest at G1-phase[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2743517-28-2. Pack Sizes: 5 mg; 10 mg; 25 mg. Product ID: HY-168620. | |
| CDK7-IN-4 | CDK7-IN-4 (compound I) is a potent CDK7 (Cyclin-dependent kinase 7) inhibitor. CDK7-IN-4 shows anticancer activity. CDK7-IN-4 inhibits the in vitro growth of cancer cell lines from a variety of histologies including colon , breast , lung , ovary and stomach , in a dose dependent manner[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2326428-25-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139342. | |
| CDK8-IN-1 | CDK8-IN-1 is a potent and selective CDK8 inhibitor with an IC50 of 3 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1629633-48-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-103492. | |
| CDK8 ligand 1 | CDK8 ligand 1 is the ligand of CDK8. CDK8 ligand 1 can be used to synthesize LL-K8-22 (HY-149209)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2924557-38-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg. Product ID: HY-168683. | |
| CDK9-IN-13 | CDK9-IN-13 (compound 38) is potent and selective CDK9 inhibitor, with an IC50 of <3 nM. CDK9-IN-13 exhibits short half-lives in rodents[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2768712-71-4. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139980. | |
| CDK-TCIP1 | CDK-TCIP1 is a bivalent molecule linking CDK9 inhibitor SNS-032 (HY-10008) to BCL6 ligand BI3812 (HY-111381). CDK-TCIP1 potently and specifically kills BCL6-overexpressing cells with EC50 of 7.7 nM for SUDHL5 cells[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 3008612-35-6. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-169244. | |
| CDN1163 | CDN1163 is an allosteric sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) activator that improves Ca2+ homeostasis. CDN1163 attenuates diabetes and metabolic disorders[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 892711-75-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101455. | |
| CDPPB | CDPPB is a selective, orally active and brain-penetrant mGluR5 allosteric modulator. CDPPB increases AKT and ERK1/2 activation and augments the BDNF mRNA. CDPPB inhibits caspase-3 activation and mitochondrial dysfunction. CDPPB improves cognitive impairment, depression, and Huntington's disease[1][2][3][4][5][6][7][8][9]. Uses: Scientific research. Category: Signaling pathways. CAS No. 781652-57-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-14569. | |
| CDYL-IN-1 | CDYL-IN-1 (compound D03) is a CDYL inhibitor, with a KD of 0.5 μM. CDYL-IN-1 can be used in the research of acute kidney injury[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2378625-66-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-161904. | |
| CE-245677 | CE-245677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases with a cellular IC50s of 4.7 and 1 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 717899-97-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-112423. | |
| CE3F4 | CE3F4 is a selective antagonist of exchange protein directly activated by cAMP (Epac1), with IC50s of 10.7 μM and 66 μM for Epac1 and Epac2(B), respectively. Uses: Scientific research. Category: Signaling pathways. CAS No. 143703-25-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108539. | |
Would you like to list your products on USA Chemical Suppliers?
Our database is helping our users find suppliers everyday.